The South African government has announced the designation of certain pharmaceutical products for domestic production. The announcement that was made by Trade and Industry Minister, Rob Davies in Pretoria, is the second wave of the designation and is in line with the amended Regulations to the Preferential Procurement Policy Framework Act (PPPFA).
According to a Department of Trade and Industry statement, the amended Preferential Procurement Regulations were promulgated last year and make provision for designation by the DTI of sectors, sub-sectors and industries identified in national economic development and industrial policies, for the procurement exclusively from domestic manufacturers.
South Africa has one of the worst disease burdens and consequently it is important to ensure supply security and development of local capacity. Minister Davies states that the designation of the pharmaceutical products will benefit the country both in terms of health and economy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze